Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment

The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes, PI3K and mTOR, are critical in this pathway. Hence, in recent years, an array of inhibitors targeting these two targets...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xianbo, Xu, Yihua, Liang, Qi, Yang, Xinwei, Huang, Jianli, Wang, Jie, Zhang, Hong, Shi, Jianyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124774/
https://www.ncbi.nlm.nih.gov/pubmed/35614940
http://dx.doi.org/10.3389/fphar.2022.875372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124774/
https://www.ncbi.nlm.nih.gov/pubmed/35614940
http://dx.doi.org/10.3389/fphar.2022.875372

Ejemplares similares